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Epidermal Growth Factor Receptor Mutation and p53
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Adenocarcinoma of the Lung
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Introduction: A progression model of atypical adenomatous hyper-
plasia (AAH) to bronchioloalveolar carcinoma (BAC) to invasive
adenocarcinoma (ADC) has been proposed. However, the genetic
alterations of the AAH-BAC-ADC sequence are not clearly estab-
lished. We examined the mutation of the epidermal growth factor
receptor (EGFR) gene and p53 protein overexpression in the AAH,
BAC, and small ADC to understand their role in the pulmonary
ADC pathogenesis.
Methods: Twenty AAH, 43 BAC (21 Noguchi type A and 22 type
B), and 47 small ADC (Noguchi type C) were enrolled in this study.
EGFR mutations at exons 18–21 and p53 protein overexpression
were examined by polymerase chain reaction-direct sequencing and
immunohistochemistry, respectively.
Results: Mutations of the EGFR gene were noted in 45 (40.9%)
lesions, which included 7 (35.0%) of AAH, 15 (34.9%) of BAC, and
23 (48.9%) of ADC. Twenty-six (23.6%) of the mutations were
detected as exon 19 deletion, 18 (16.4%) as exon 21 point mutation,
and 1 (0.9%) as exon 18 point mutation. Overexpression of p53
protein was found in 19 (17.2%) lesions, none of AAH, 4 (9.8%) of
BAC, and 15 (31.9%) of ADC. Multivariate analysis showed that
p53 overexpression was associated with invasive ADC (P  0.003).
Conclusions: High frequency and similar incidence of EGFR mu-
tation in AAH, BAC, and ADC support that EGFR gene mutation
occurs in the early stage of pulmonary ADC development and tumor
initiation from the preneoplastic lung parenchyma to neoplastic
conditions. On the contrary, p53 overexpression is a late event
during tumor development and plays a role in the progression of the
peripheral pulmonary ADC.
Key Words: Epidermal growth factor receptor (EGFR), p53, Ade-
nocarcinoma, Lung neoplasm, Carcinogenesis.
(J Thorac Oncol. 2010;5: 964–969)
Peripheral pulmonary carcinogenesis has been known toinvolve multiple genetic and epigenetic alterations as well
as morphologic alterations of normal bronchioloalveolar ep-
ithelium.1,2 Atypical adenomatous hyperplasia (AAH) and
bronchioloalveolar carcinoma (BAC), as preinvasive lesions,
are major targets to study multistep development of periph-
eral pulmonary adenocarcinoma (ADC).3,4 Most reports un-
derwent using incidentally found small lesions including
AAH or BAC in the resected lung harboring advanced can-
cer, because AAH or BAC lesions are small, which are
undetected preoperatively.5,6 However, recent advances of
radiologic equipments enable to detect small peripheral lung
nodule showing ground glass opacity.7–9 Many radiologic-
pathologic correlation studies showed that ground glass opac-
ity lesions matched well with the preinvasive to invasive
neoplasia with the hypothesis of multistep sequence of AAH,
BAC, and small ADC with BAC features.8 The demands for
accurate pathologic diagnoses and investigation of genetic
alterations during the AAH, BAC, small ADC sequence are
increasing. Recent advances in molecular genetics have re-
vealed that multiple genetic alterations are required for pe-
ripheral lung tumor development and progression.5,10–12 The
mutation of epidermal growth factor receptor (EGFR) gene
has been detected in the preinvasive lesions such as AAH or
BAC as well as ADC.4,5,8 The deletion in exon 19 and point
mutation in exon 21 are more frequently found in the patients
who are females, nonsmokers, and Asian.13,14 The p53 tumor
suppressor gene has been known that genetic alterations
contribute to tumor progression and metastasis.15–17 Mutation
of p53 is very frequent in lung cancer and occurs in 50% of
non-small cell lung cancer and 75% of small cell lung
cancer.18 Approximately 20% of them are in nonsense muta-
tion or in splicing sites with truncated messenger RNA. They
could not be detected by immunohistochemistry, and se-
quencing techniques are required for their detection.19 Most
of the mutations identified in lung cancers are missense
mutations. The half-life of the wild-type p53 protein is short
and usually not detected by immunohistochemical methods.
By contrast, missense mutations are frequently associated
with a prolonged half-life of the mutant protein that leads to
the accumulation of p53 protein in nucleus. Because of the
large spectrum of hotspots,20 mutational analysis of p53 gene
is less suitable for clinical application. During the multistage
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pathogenesis, the p53 gene alteration is thought to have an
important role, but its relation with progression model of
peripheral pulmonary carcinogenesis is not clearly estab-
lished.17 To investigate the roles of EGFR mutations and p53
protein overexpression in the multistage pathogenesis of
peripheral ADC, we examined these molecular alterations
among AAH, BAC, and small ADC with BAC features.
PATIENTS AND METHODS
Patients and Specimens
A total of 89 patients who had small peripheral neo-
plastic lesions (AAH, BAC, and invasive ADC with BAC
features) were selected from the archives of the Department
of Pathology at the Seoul National University Bundang Hos-
pital, Korea. All patients underwent curative surgical resec-
tion during May 2005 to August 2009. Of these, 14 patients
had synchronous multiple lesions (2–6 per resection). In
total, 110 surgically resected lesions measuring 2.0 cm or less
were included. Histopathologic diagnoses of preinvasive and
invasive ADC were based on the World Health Organization
classification and Noguchi’s criteria.21,22 Strict criteria were
applied to the diagnosis of BAC, defined as “an adenocarci-
noma with a pure bronchioloalveolar growth pattern and no
evidence of stromal, vascular, or pleural invasion.” Because
AAH is considered as a precursor lesion and Noguchi types A
and B represent the noninvasive BAC (as defined by the
World Health Organization classification), we combined
three categories and compared their findings with those
present in small ADC with BAC component (Fig. 1). These
patients were not treated with neoadjuvant chemotherapy or
radiation therapy before operation. Clinicopathological pa-
rameters such as age, gender, smoking history, and patho-
logic stage were evaluated by reviewing medical charts and
pathologic records. This study was approved by the Institu-
tional Review Board.
Mutational Analysis of the EGFR
We analyzed EGFR mutations at exon 18–21 by poly-
merase chain reaction (PCR) and direct DNA sequencing
method as described previously.23 The DNA was isolated
from formalin-fixed and paraffin-embedded tissues. PCR am-
plification was performed in a total volume of 20 L con-
taining 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 2.5 mM deoxynucleotide triphosphates, 0.5 M of
each primer, 0.9 units Taq DNA polymerase (Takara Bio,
Shiga, Japan). After preincubation at 94°C for 2 minutes,
DNA was amplified for 35 cycles under the following con-
ditions: denaturation at 94°C for 30 seconds, annealing, and
elongation at 72°C for 30 seconds. The PCR products were
processed with BigDye Terminator version 3.1 cycle se-
quencing kit (Applied Biosystems, Foster, CA), and sequence
data were generated with the ABI PRISM 3100 DNA Ana-
lyzer (Applied Biosystems). All sequence variants were con-
firmed by sequencing the products of independent PCR am-
plifications in both directions.
Immunohistochemistry of p53 Protein
Expression
Formalin-fixed and paraffin-embedded tissue sections
were deparaffinized and rehydrated in graded alcohol for the
immunohistochemical analysis. Antigen retrieval was
achieved by proteinase K digestion for 10 minutes, and the
primary anti-p53 antibody (a mouse monoclonal antibody,
DO-7, 1:1000; DAKO, Glostrup, Denmark) was applied. The
sections were incubated for 1 hour at room temperature with
biotinylated goat anti-mouse antibody and with peroxidase-
conjugated streptavidin. For a chromogen, 3,3-diaminoben-
zidine tetrahydrochloride (0.05%) was used. The sections
were each classified as p53 negative or positive. Nuclear
FIGURE 1. Representative histologic feature for lesions. A,
Atypical cuboidal cells resembled type II pneumocyte with
little nuclear pleomorphism in atypical adenomatous hyper-
plasia (AAH). B, Atypical tall columnar cells lining with intact
underlying alveolar space in bronchioloalveolar carcinoma
(BAC). C, Invasive adenocarcinoma (ADC) with central
fibrosis.
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staining in10% of tumor cells was considered positive. The
interpretation of p53 expression was done by two pathologists
(S.B.Y. and J.-H.C.) in a blinded manner.
Statistical Analysis
Fisher exact test or Pearson’s 2 test were used to
assess the relationships of the clinicopathologic parameters
and molecular changes. Statistical significance was defined as
p  0.05. Statistical analysis was performed using SPSS
version 17.0 (Systat, Chicago, IL).
RESULTS
Patient Characteristics
The clinicopathological characteristics are summarized
in Table 1. The patients (40 men and 49 women) were aged
34 to 81 (median age  60 years) at surgery. All patients
underwent curative resections: bilobectomy in 3 patients,
unilobectomy in 57, segmentectomy in 7, and wedge resec-
tion in 22. A total of 110 lesions were examined from 89
patients. All 110 cases consisted of 20 AAH, 21 BAC type A,
22 BAC type B, and 47 invasive ADC type C. All cases of
BAC in this series were of nonmucinous type, and invasive
ADCs were mixed subtype with BAC component. The max-
imum diameter of the lesions ranged between 2 and 20 mm
and median (a cutoff value of the size) was 12 mm; 2 and 10
mm for AAH, 2 and 19 mm for BAC, and 5 and 20 mm for
ADC, respectively.
Mutational Analyses of EGFR Genes
EGFR mutations were found in 35.0% (7 of 20) of
AAH, 34.9% (15 of 43) of BAC, and 48.9% (23 of 47) of
ADC, respectively (Table 2). The deletion in exon 19 was
found in 26 lesions and point mutation in exon 21 (L858R)
was found in 18 lesions. The deletion range of nucleotide in
exon 19 was variable. The 2235–2246del was most common,
followed by 2239–2256del and 2240–2254del. The point
mutation in exon 18 (F712L) was detected in an ADC. The
nucleotide change of exon 18 was 2134TC and it was
confirmed in independent PCR product. The frequency of
EGFR mutations was similar among the AAH, BAC, and
ADC (Table 2). The EGFR mutations were more frequently
observed in female and nonsmoker patients with large tumor
size.
p53 Protein Overexpression
The overexpression of p53 protein was detected in
17.2% (19 of 110) lesions including 9.8% (4 of 43) of BAC
and 31.9% (15 of 47) of ADC. None of AAH showed p53
protein overexpression, and expression of p53 was frequently
seen in the invasive ADC (Table 3). The frequency of p53
protein expression tended to be higher in the old-aged pa-
TABLE 1. Clinicopathologic Features Related with EGFR Mutation and p53 Expression of 110
Lesions in 89 Patients, Respectively
Total (n  110)
EGFR Mutation
pa
p53 Expression
paNegative Positive Negative Positive
Sex
Male 55 (54.8%) 44 (80.4%) 11 (19.6%) 0.000 46 (82.4%) 9 (17.6%) 0.801
Female 55 (45.2%) 21 (45.2%) 34 (54.8%) 45 (83.3%) 10 (16.7%)
Age
65 45 (37.6%) 26 (71.4%) 19 (28.6%) 0.816 33 (71.4%) 12 (28.6%) 0.030
65 65 (62.4%) 39 (60.3%) 26 (39.7%) 58 (89.7%) 7 (10.3%)
Smoking
No 63 (53.8%) 30 (56.0%) 33 (44.0%) 0.005 51 (80.0%) 12 (20.0%) 0.569
Yes 47 (46.2%) 35 (74.4%) 12 (25.6%) 40 (86.0%) 7 (14.0%)
Tumor size (mm)
12 46 (38.7%) 22 (58.3%) 24 (41.7%) 0.042 35 (75.0%) 11 (25.0%) 0.118
12 64 (61.3%) 43 (68.4%) 21 (31.6%) 56 (87.7%) 8 (12.3%)
a Pearson’s 2 test.
TABLE 2. EGFR Gene Mutation
Histology
(n)
No. of
Mutation
(%)
No. of Mutation
Exon 19 Exon 21 Exon 18
AAH (20) 7 (35.0%) 2235–2246del (1) 2573TG (2)
2239–2253del (1)
2239–2256del (1)
2240–2254del (2)
BAC (43) 15 (34.9%) 2235–2246del (3) 2573TG (8)
2235–2249del (1)
2239–2253del (1)
2239–2256del (2)
ADC (47) 23 (48.9%) 2235–2246del (4) 2573TG (8) 2134TC (1)
2236–2250del (2)
2239–2253del (1)
2239–2256del (1)
2240–2254del (2)
2240–2257del (1)
2252–2275del (1)
2252–2276del (1)
2253–2276del (1)
Total
(110)
45 (40.9%) 26 (23.6%) 18 (16.4%) 1 (0.9%)
AAH, atypical adenomatous hyperplasia; BAC, bronchioloalveolar carcinoma;
ADC, adenocarcinoma.
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tients but it was not correlated with smoking history or EGFR
mutation status.
Multiple Lesions in a Patient
There were 14 patients with multiple small lesions in
their resected specimens (Table 4). For one patient, who had
four AAHs, a deletion in exon 19 was noted in one AAH and
no mutation in the other three lesions. Another patient (no.
13) with triple lesions (AAH, BAC, and ADC) harbored an
EGFR mutation in the ADC only. There was one patient (no.
10) whose lesions (BAC and ADC) had same L858R muta-
tion. Except one case, there were no patients with identical
EGFR mutation in multiple lung lesions.
DISCUSSION
In the multistage progression of the tumor, the accu-
mulation of genetic changes is essential, and various molec-
ular alterations playing roles in carcinogenesis of gastric24,25
and colorectal26,27 neoplasm have been studied including
oncogene, tumor suppressor gene, and mismatch repair gene.
The development of lung carcinoma is also related with the
multiple genetic alterations.10–12 In this study, we found
differential molecular changes during the peripheral lung
ADC development. The frequency of EGFR mutation among
AAH, BAC, and ADC was similar, which is consistent with
previous reports that EGFR gene alteration occurs in the early
steps of pulmonary ADC development.28,29
On the contrary, p53 overexpression was significantly
more frequent in the ADC; 6.3% of noninvasive lesions
including BAC/AAH and 31.9% of invasive ADC. This result
supported that p53 overexpression might be related to inva-
siveness in the tumor progression of pulmonary ADC rather
than initiation. In addition, smoking history or gender was not
correlated with p53 overexpression in this study. Our results
seemed to be different from previous reports at least on the
two points. First, abnormalities of p53 have been known to be
related with early event in lung carcinogenesis.17,30,31 How-
ever, with extensive review of published reports, p53 alter-
ations in the early lesions were more prevalent in squamous
cell carcinoma of the lung than in ADC.17,30,31 In the bron-
chial carcinogenesis, p53 protein expression was increased
from preneoplasia to invasive lesion, which suggested that
the alteration may be associated with early event.30,31 In the
AAH, p53 protein was also detected with low level of
TABLE 3. Frequency of p53 Protein Expression
Histology
p53 Protein Expression
pa
EGFR Mutation Negative
p53 Protein Expression
pa
EGFR Mutation Positive
p53 Protein Expression
paNegative Positive Negative Positive Negative Positive
AAH 20 (100.0%) 0 (0.0%) 0.298 13 (100.0%) 0 (0.0%) 0.539 7 (100.0%) 0 (0.0%) 1.000
BAC 39 (90.2%) 4 (9.8%) 0.607 25 (89.3%) 3 (10.7%) 1.000 14 (93.3%) 1 (6.7%) 1.000
Noguchi type A 20 (95.2%) 1 (4.8%) 13 (92.9%) 1 (7.1%) 7 (100.0%) 0 (0.0%)
Noguchi type B 19 (86.4%) 3 (13.6%) 12 (85.7%) 2 (14.3%) 7 (87.5%) 1 (12.5%)
ADC 32 (62.5%) 15 (37.5%) 0.010 17 (70.8%) 7 (29.2%) 0.157 15 (65.2%) 8 (34.8%) 0.061
Total 91 (82.8%) 19 (17.2%) 55 (84.6%) 10 (15.4%) 36 (80.0%) 9 (20.0%)
a Fisher’s exact test.
AAH, atypical adenomatous hyperplasia; BAC, bronchioloalveolar carcinoma; ADC, adenocarcinoma.
TABLE 4. Synchronous Multiple Lesions
Patient Sex Smoking Histology
No. of
Lesions
EGFR
Mutation
1 M Yes BAC 2 Wild type
BAC Wild type
2 M Yes ADC 2 Wild type
BAC Wild type
3 M Yes ADC 6 Wild type
BAC del E746-T750
BAC Wild type
BAC Wild type
AAH del L747-T751
AAH Wild type
4 M Yes ADC 2 Wild type
AAH L858R
5 M Yes BAC 2 Wild type
BAC del L747-S752
6 M Yes ADC 2 del L747-T751
BAC Wild type
7 M Yes BAC 2 Wild type
BAC Wild type
8 M Yes BAC 2 Wild type
BAC Wild type
9 M Yes BAC 2 Wild type
BAC del L747-T751
10 F No ADC 2 L858R
BAC L858R
11 F No ADC 2 del L747-S752
ADC Wild type
12 F No AAH 4 del L747-S752
AAH Wild type
AAH Wild type
AAH Wild type
13 F No ADC 3 del L747-T751
BAC Wild type
AAH Wild type
14 F No ADC 2 L858R
BAC L860Q
AAH, atypical adenomatous hyperplasia; BAC, bronchioloalveolar carcinoma;
ADC, adenocarcinoma.
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expression compared with carcinoma, which implicated that
AAH can be preneoplastic condition of peripheral ADC.32
However, unlike our study, most AAH lesions in the previous
studies were incidentally found in the resected lung harboring
invasive ADC of which multiple small clonal or subclonal
patches containing molecular abnormalities could be present
in normal or slightly abnormal epithelium.3–6,28 Second, p53
gene alteration has been known to be early molecular event
strongly related with cigarette smoking. But in this study of
peripheral pulmonary ADC development, there was no sig-
nificant association with p53 overexpression and smoking
history. Because ADC is the most frequent type of lung
cancer in never-smokers, p53 overexpression may occur
independent of smoking exposure in the peripheral pulmo-
nary ADC. Overexpression of p53 protein is associated with
invasiveness in the ADC development, which corresponds
well with previous studies that p53 overexpression was re-
lated with poor prognostic indicators in the ADC than squa-
mous cell carcinoma of the lung. The prognostic implications
of p53 gene mutations and protein expression in non-small
cell lung cancer have been reported in several studies.19,33
However, the discrepancy between mutation and protein
expression has been noted in some studies.19,33 That is why
missense mutation of the p53 gene usually but not always
prolongs the half-life of the protein and results in nuclear
accumulation of the p53 protein, which can be detected by
immunohistochemistry.17 Unfortunately, we could not exam-
ine p53 alterations in the DNA level because of insufficient
tissue. Further study is mandatory to understand their role for
multistep peripheral lung carcinogenesis. There were 14 pa-
tients with multiple lesions and only one patient with BAC
and ADC had the same L858R mutation in each lesion. For
the most of patients with multiple lesions, EGFR genetic
alterations were different from each other, which suggests
that synchronous multiple lesions could acquire independent
genetic aberrations.8 This result also suggests that genetic
change may occur separately even in the same patient with
multiple lesions.
In summary, there was a significant difference between
the EGFR gene mutation and expression of p53 during
multistep pulmonary small ADC development. Because,
EGFR mutations have been found in the nonmalignant lung
tissue adjacent to invasive peripheral ADC,33 mutations of
EGFR are early events that play a role in tumor initiation. By
contrast, p53 protein overexpression was more frequently
found in invasive ADC than noninvasive lesions, which
suggests that p53 expression is a late event with tumor
progression.
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